Dr. Nigel Brown to Serve as Senior Adviser to MedAvante

Experienced Thought Leader Will Help Build Momentum in Solutions for Digital Clinical Study Data

Hamilton, NJ (December 8, 2015) – MedAvante, Inc., a leading global provider of science-driven, technology-enabled signal detection solutions for clinical trials of treatments for central nervous system (CNS) disorders announced that Dr. Nigel Brown, former Corporate Vice President of Business Development and Strategy at Covance Inc., will serve as a senior adviser to the company.

Dr. Brown will counsel MedAvante on continuing its progress as a pioneer in electronic clinical outcome assessment (eCOA) solutions that improve data quality in CNS studies, enhance the ability to detect a clinical signal and reduce burden for investigative sites. He is CEO of Princeton Healthcare Advisory LLC and recently completed a decade of service as a member of the Executive Committee at Covance, now a division of LabCorp Holdings. In that role Brown was responsible for M&A, licensing and strategic partnership deals, including a groundbreaking $2.2Bn 10-year strategic alliance broadly regarded as the largest and most creative partnership deal in the history of the contract research organization (CRO) sector.

“Nigel Brown is one of the most accomplished and respected thought leaders in pharma research and development with strong track record of improving R&D cycle times through adoption of innovative technology,” said MedAvante CEO Paul M. Gilbert. “His extensive experience and keen understanding of where clinical research is heading will be a tremendous asset not only for MedAvante but for our clients as well.”

In his advisory capacity, Brown will work closely with MedAvante’s senior leadership team, building on more than six years of experience capturing digital study data using tablet devices and the cloud, capabilities offered today through the Virgil® Investigative Study Platform.

“I am excited about the significant opportunity to optimize signal detection in clinical trials, particularly for challenging clinician-reported outcomes such as the PANSS, MADRS and HAM-D, and then extending that tremendous value to all types of clinical outcomes,” said Brown. “MedAvante’s record of digitally compiling more than two million pages of source documents without losing a single data point is unmatched by anyone, and they are just at the beginning of a breakthrough paradigm shift in clinical research.”

“Nigel will play a key role in leveraging MedAvante’s leadership as the pioneer in electronic source (eSource) data for use in global CNS drug trials, the ‘torture test’ for drug development,” said Gilbert. “His insight and creativity will help us in CNS as well as other therapeutic areas by further enhancing the Virgil platform with more digital capabilities on the tablet and smarter data in the web portal.”

Supported by scientific services to qualify clinicians for studies and review assessment quality, Virgil puts the benefits of MedAvante’s pioneering work to standardize COA into the hands of any clinician at any site worldwide. The Virgil platform is now being used in large clinical trials covering various therapeutic indications at trial sites across the Americas, Eastern and Western Europe and the Asia Pacific region.

About MedAvante, Inc.
MedAvante is the leading global provider of technology-enabled signal detection solutions in clinical trials of treatments for central nervous system (CNS) disorders with more than a decade of experience improving scale-based diagnostic and outcome measurements. MedAvante standardizes rating scale administration and scoring through two primary services: the Virgil® Investigative Study Platform for site-based assessments; and MedAvante® Central Ratings for live assessments by highly calibrated remote central clinicians. Supported by operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.